Innovent Biologics, Inc. (IVBXF)
OTCMKTS
· Delayed Price · Currency is USD
5.94
0.00 (0.00%)
May 14, 2025, 4:00 PM EDT
Innovent Biologics Employees
Innovent Biologics had 5,659 employees as of December 31, 2024. The number of employees increased by 787 or 16.15% compared to the previous year.
Employees
5,659
Change (1Y)
787
Growth (1Y)
16.15%
Revenue / Employee
$228,102
Profits / Employee
-$2,291
Market Cap
10.56B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Endo Inc. | 3,116 |
Tian'an Technology Group | 8 |
CytoDyn | 9 |
Glass House Brands | 374 |
Elite Pharmaceuticals | 64 |
Northwest Biotherapeutics | 25 |
Silence Therapeutics | 116 |
American Oncology Network | 1,914 |
Innovent Biologics News
- 8 days ago - Bispecific vs. Bispecific: Innovent Announces First Patient Dosed in the Phase 2 Clinical Study ... - GuruFocus
- 8 days ago - Bispecific vs. Bispecific: Innovent Announces First Patient Dosed in the Phase 2 Clinical Study of Efdamrofusp Alfa (IBI302), a First-in-class Anti-VEGF and Anti-Complement Bispecific Fusion Protein for the Treatment of Diabetic Macular Edema - PRNewsWire
- 9 days ago - Innovent Announces Oral Presentation of Full Phase 2 Clinical Data for Efdamrofusp Alfa (IBI302), First-in-class anti-VEGF/complement Bispecific Fusion Protein at ARVO 2025 - PRNewsWire
- 15 days ago - Innovent Announces First Patient Dosed in Phase 1 Study of IBI3020, Global First-in-class Dual Payload CEACAM5 ADC, in Patients with Advanced Malignancies - PRNewsWire
- 17 days ago - Innovent Biologics Inc (IVBIY) Showcases Groundbreaking Preclinical Data at AACR 2025 | IVBIY ... - GuruFocus
- 17 days ago - 2025 AACR | Innovent Presents Preclinical Data of Multiple Novel Molecules including Bispecific ... - GuruFocus
- 17 days ago - 2025 AACR | Innovent Presents Preclinical Data of Multiple Novel Molecules including Bispecific and Tri-specific Antibodies and Bispecific ADCs - PRNewsWire
- 19 days ago - Innovent Biologics Inc (IVBIY) Secures NMPA Approval for Limertinib as First-Line Treatment for ... - GuruFocus